We've updated our Privacy Policy to make it clearer how we use your personal data. We use cookies to provide you with a better experience. You can read our Cookie Policy here.


Crystal Bank to Accelerate Structure-Based Drug Discovery

Listen with
Register for free to listen to this article
Thank you. Listen to this article using the player above.

Want to listen to this article for FREE?

Complete the form below to unlock access to ALL audio articles.

Read time: Less than a minute

Sareum Holdings plc has announced the launch of “Crystal Bank”, designed to accelerate drug discovery by accessing protein structure data.

Sareum’s Crystal Bank is a collection of therapeutically relevant protein targets on which the Company is able to generate structural data that illustrates the nature of how potential drug candidates associate with a target protein.

This information is designed to assist the accelerated discovery of improved therapies against many important diseases including cancer, inflammation and metabolic disorders.

Commenting on the announcement, Sareum’s Chief Executive Officer, Dr Tim Mitchell, said, “This exciting new extension to our capabilities provides us with an important additional source of revenues, and very effectively demonstrates our success in solving the structures of therapeutically relevant proteins, a key component of our core drug discovery business.”